BioNTech ADR saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 66 to 79.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the best-performing stocks typically have an RS Rating of over 80 in the early stages of their moves. See if BioNTech ADR can continue to show renewed price strength and hit that benchmark.
While it's not currently an ideal time to buy shares, see if the stock is able to establish and enter a buy zone in heavy trade.
The company reported negative growth for both sales and earnings last quarter. BioNTech ADR is expected to release its next quarterly numbers on or around May 5.
BioNTech ADR holds the No. 103 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
